Monday, September 15, 2008

Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen

STOCKHOLM, Sweden & THOUSAND OAKS, Calif. – Sept. 15, 2008 – Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance(R) (palifermin) and Stemgen(R) (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret(R) (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value.

Posted in Press Releases, Product News